Clinical Trials Logo

Clinical Trial Summary

Prior to the use of plasma products, thrombotic thrombocytopenic purpura (TTP) was usually a fatal condition. During plasma exchange therapy, patients need transfusion plasma that is blood group specific. Transfusing a patient with an incorrect blood group may have fatal consequences. Uniplas is a universally applicable human plasma, which can be administered irrespective of the patient's blood group. This study will test the safety and efficacy of Uniplas in comparison to cryosupernatant plasma in treatment of patients with TTP.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00411801
Study type Interventional
Source Octapharma
Contact
Status Terminated
Phase Phase 3
Start date May 2007
Completion date February 2008

See also
  Status Clinical Trial Phase
Completed NCT03393975 - A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Not yet recruiting NCT06441578 - A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Recruiting NCT05714969 - A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Phase 2
Completed NCT00937131 - The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Phase 2
Recruiting NCT04683003 - A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Phase 3
Available NCT05770219 - Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)